SCHEMBL5476263

SCHEMBL5476263

O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1ccc[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 7/20 1.00
JAK2 O60674 2/20 1.00
LRRK2 Q5S007 2/20 0.86
RET P07949 6/20 0.62
FLT3 P36888 3/20 0.62
ALK Q9UM73 3/20 0.62
RAF1 P04049 2/20 0.62
ABL1 P00519 2/20 0.62
PIK3C3 Q8NEB9 1/20 0.62
PDPK1 O15530 5/20 0.60
PDGFRB P09619 3/20 0.60
PDGFRA P16234 2/20 0.60
FLT1 P17948 2/20 0.60
KDR P35968 2/20 0.60
CHEK1 O14757 2/20 0.60
AURKA O14965 1/20 0.57
DAPK3 O43293 1/20 0.57
PRKD3 O94806 1/20 0.57
MAP4K4 O95819 1/20 0.57
PAK4 O96013 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5476260 1.00 JAK3 (1.00) JAK3JAK2LRRK2RETFLT3
SCHEMBL21585712 0.93 LRRK2 (1.00) JAK3JAK2LRRK2RETFLT3
SCHEMBL6962375 0.81 JAK3 (0.69) JAK3JAK2LRRK2RETFLT3
SCHEMBL6962386 0.81 JAK3 (0.69) JAK3JAK2LRRK2RETFLT3
SCHEMBL19442413 0.81 JAK3 (0.69) JAK3JAK2LRRK2RETFLT3
SCHEMBL5988205 0.80 PDPK1 (0.68) JAK3JAK2LRRK2RETFLT3
SCHEMBL19442446 0.80 JAK3 (0.66) JAK3JAK2LRRK2RETFLT3
SCHEMBL5989169 0.78 JAK3 (0.68) JAK3JAK2LRRK2RETFLT3
SCHEMBL6174867 0.78 JAK3 (0.64) JAK3JAK2LRRK2RETFLT3
SCHEMBL5728456 0.77 JAK3 (0.63) JAK3JAK2LRRK2RETFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US claimed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP claimed
EP-1366038-B1 CDK-1 INHIBITOR OXINDOLES AND THE APPLICATION THEREOF IN THERAPEUTICS AVENTIS PHARMA SA (FR) 2005-08-31 EP claimed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO claimed
US-20040110770-A1 Oxindoles which are inhibitors of CDK-1 and their application in therapeutics AVENTIS PHARMA SA (FR) 2004-06-10 US claimed
US-20180153902-A1 SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION HOWARD HUGHES MEDICAL INSTITUTE 2018-06-07 US disclosed
US-9782417-B2 Methods of increasing satellite cell proliferation with kinase inhibitors PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) 2017-10-10 US disclosed
US-20160220580-A1 SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-08-04 US disclosed
US-9248185-B2 Methods of increasing satellite cell proliferation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2016-02-02 US disclosed
US-20140294855-A1 SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-10-02 US disclosed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP disclosed
EP-1366038-B1 CDK-1 INHIBITOR OXINDOLES AND THE APPLICATION THEREOF IN THERAPEUTICS AVENTIS PHARMA SA (FR) 2005-08-31 EP disclosed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO disclosed
US-20040110770-A1 Oxindoles which are inhibitors of CDK-1 and their application in therapeutics AVENTIS PHARMA SA (FR) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110770-A1 Oxindoles which are inhibitors of CDK-1 and their application in therapeutics CCNI, CCNH, CDK1 JAK3 249/4885JAK2 302/4885LRRK2 3289/4885
US-20180153902-A1 SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION MKI67, MYLK2, MYH2 JAK3 4267/4885JAK2 4529/4885LRRK2 2584/4885
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 JAK3 2629/4885JAK2 4245/4885LRRK2 1753/4885
US-20140294855-A1 SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION MKI67, MYLK2, MYH2 JAK3 4231/4885JAK2 4526/4885LRRK2 2579/4885
US-20160220580-A1 SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION MKI67, MYLK2, MYH2 JAK3 4267/4885JAK2 4529/4885LRRK2 2584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.